ValenzaBio, Pierre Fabre sign licensing, commercialization deal

The Bethesda-based biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre Thursday announced the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *